Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 11/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7610832 | 0.98 | CHRM1 (0.60) | CHRM1CHRM4 | |
| SCHEMBL7614590 | 0.97 | CHRM1 (0.60) | CHRM1CHRM4 | |
| Oxalic Acid SCHEMBL7614557 | 0.84 | CHRM1 (0.69) | CHRM1CHRM4 | |
| SCHEMBL7617535 | 0.84 | CHRM1 (0.58) | CHRM1CHRM4SIGMAR1 | |
| SCHEMBL7611994 | 0.83 | CHRM1 (0.77) | CHRM1CHRM4SIGMAR1 | |
| Oxalic Acid SCHEMBL7614588 | 0.83 | CHRM1 (0.69) | CHRM1CHRM4 | |
| Oxalic Acid SCHEMBL7610828 | 0.83 | CHRM1 (0.69) | CHRM1CHRM4 | |
| SCHEMBL7620935 | 0.83 | CHRM1 (0.59) | CHRM1CHRM4SIGMAR1 | |
| SCHEMBL7617889 | 0.83 | CHRM1 (0.55) | CHRM1CHRM4SIGMAR1 | |
| SCHEMBL7617463 | 0.82 | CHRM1 (0.78) | CHRM1CHRM4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0734259-B1 | Use of piperidine compounds in the treatment of schizophrenia | NOVO NORDISK AS (DK) | 2002-06-12 | — | — | EP | disclosed |
| US-5773452-A | ALZHEIMER'S DISEASE; COGNITION ACTIVATORS | NOVO NORDISK ALS (DK) | 1998-06-30 | — | — | US | disclosed |
| US-5753683-A | SCHIZOPHRENIA | NOVO NORDISK A/S (DK) | 1998-05-19 | — | — | US | disclosed |
| US-5750541-A | 3-(1,2,5-THIA OR OXADIAZOL-3-YL)-1,2,5,6-PYRIDINE DERIVATIVES; SCHIZOPHRENIFORM DISEASES; SIDE EFFECT REDUCTION | NOVO NORDISK A/S (DK) | 1998-05-12 | — | — | US | disclosed |
| US-5744489-A | ADMINISTERING CERTAIN 1,2,5-THIADIAZOLE AND 1,2,5-OXADIAZOLE COMPOUNDS | GREENWOOD BEVERLEY (US) | 1998-04-28 | — | — | US | disclosed |
| EP-0732925-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995017185-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1995-06-29 | — | — | WO | disclosed |